title: Current perspectives on the therapeutic aspects of chronic myelogenous leukemia.
abstract: BACKGROUND
  Chronic myelogenous leukemia (CML) is a myeloproliferative disorder arising from the malignant transformation of normal myeloid cells. Its genetic hallmark is the presence of Philadelphia chromosome translocation which results in fusion of the breakpoint cluster region and abelson genes.
  
  
  METHODS
  The study aims to evaluate the current therapeutic practices used through tyrosine kinase inhibitors, as well as the novel methods underlined by nucleotide- and mAb-based therapies. It is followed by a thorough review on recent research developments for each of the anti-CML-based therapeutic approaches, their drawbacks and latest research especially to overcome drug resistance problems. The detailed analysis of specific granted patents highlighting different claims and downstream applications is also presented.
  
  
  CONCLUSIONS
  In the current scenario, the targeted therapy based on small molecules, mAbs, nucleic acid and nanoparticles have been formulated but optimization and improvement of the approaches are required to overcome the risks and obstacles in anti-CML-based therapy. The current research is paving the way for combinatorial approaches to address the problems of efficacy, toxicity and drug resistance.
authors.affiliation: Jaypee Institute of Information Technology, Department of Biotechnology , A-10, Sector-62, Noida, UP, 201307 , India +91 120 2594210 ; +91 120 2400986 ; reema.gabrani@jiit.ac.in.
authors.forename: Asiem
authors.initials: A
authors.lastname: Bhaskar
authors.forename: Kiran
authors.initials: K
authors.lastname: Raturi
authors.forename: Shweta
authors.initials: S
authors.lastname: Dang
authors.forename: Reema
authors.initials: R
authors.lastname: Gabrani
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000502:physiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D053758:Nanoparticles / Q000627:therapeutic use; D010330:Patents as Topic; D034622:RNA Interference; D050799:STAT5 Transcription Factor / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D050799:STAT5 Transcription Factor; D016044:Fusion Proteins, bcr-abl
keywords: RNA interference; T315I mutation; breakpoint cluster region–abelson oncogene; imatinib mesylate; mAbs; small molecule inhibitors